vs

Side-by-side financial comparison of ASPEN AEROGELS INC (ASPN) and Health Catalyst, Inc. (HCAT). Click either name above to swap in a different company.

Health Catalyst, Inc. is the larger business by last-quarter revenue ($74.7M vs $41.3M, roughly 1.8× ASPEN AEROGELS INC). Health Catalyst, Inc. runs the higher net margin — -121.9% vs -176.4%, a 54.5% gap on every dollar of revenue. On growth, Health Catalyst, Inc. posted the faster year-over-year revenue change (-6.2% vs -66.4%). ASPEN AEROGELS INC produced more free cash flow last quarter ($13.7M vs $9.6M). Over the past eight quarters, Health Catalyst, Inc.'s revenue compounded faster (-0.0% CAGR vs -33.9%).

Aspen Aerogels Inc is a leading manufacturer of high-performance aerogel-based insulation and thermal management materials. It serves core sectors including renewable energy, oil and gas infrastructure, aerospace, commercial construction and industrial manufacturing, with key markets across North America, Europe and Asia-Pacific. Its products are prized for superior thermal resistance, fire safety and lightweight performance for harsh operating conditions.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

ASPN vs HCAT — Head-to-Head

Bigger by revenue
HCAT
HCAT
1.8× larger
HCAT
$74.7M
$41.3M
ASPN
Growing faster (revenue YoY)
HCAT
HCAT
+60.2% gap
HCAT
-6.2%
-66.4%
ASPN
Higher net margin
HCAT
HCAT
54.5% more per $
HCAT
-121.9%
-176.4%
ASPN
More free cash flow
ASPN
ASPN
$4.0M more FCF
ASPN
$13.7M
$9.6M
HCAT
Faster 2-yr revenue CAGR
HCAT
HCAT
Annualised
HCAT
-0.0%
-33.9%
ASPN

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ASPN
ASPN
HCAT
HCAT
Revenue
$41.3M
$74.7M
Net Profit
$-72.9M
$-91.0M
Gross Margin
-55.5%
Operating Margin
-170.3%
-115.3%
Net Margin
-176.4%
-121.9%
Revenue YoY
-66.4%
-6.2%
Net Profit YoY
-741.7%
-340.3%
EPS (diluted)
$-0.87
$-1.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASPN
ASPN
HCAT
HCAT
Q4 25
$41.3M
$74.7M
Q3 25
$73.0M
$76.3M
Q2 25
$78.0M
$80.7M
Q1 25
$78.7M
$79.4M
Q4 24
$123.1M
$79.6M
Q3 24
$117.3M
$76.4M
Q2 24
$117.8M
$75.9M
Q1 24
$94.5M
$74.7M
Net Profit
ASPN
ASPN
HCAT
HCAT
Q4 25
$-72.9M
$-91.0M
Q3 25
$-6.3M
$-22.2M
Q2 25
$-9.1M
$-41.0M
Q1 25
$-301.2M
$-23.7M
Q4 24
$11.4M
$-20.7M
Q3 24
$-13.0M
$-14.7M
Q2 24
$16.8M
$-13.5M
Q1 24
$-1.8M
$-20.6M
Gross Margin
ASPN
ASPN
HCAT
HCAT
Q4 25
-55.5%
Q3 25
28.5%
52.6%
Q2 25
32.4%
Q1 25
29.0%
Q4 24
38.3%
Q3 24
41.8%
47.5%
Q2 24
43.8%
Q1 24
37.2%
Operating Margin
ASPN
ASPN
HCAT
HCAT
Q4 25
-170.3%
-115.3%
Q3 25
-4.6%
-22.9%
Q2 25
-6.6%
-46.0%
Q1 25
-380.2%
-25.4%
Q4 24
12.0%
-22.0%
Q3 24
14.8%
-17.9%
Q2 24
17.0%
-20.8%
Q1 24
2.6%
-30.5%
Net Margin
ASPN
ASPN
HCAT
HCAT
Q4 25
-176.4%
-121.9%
Q3 25
-8.7%
-29.1%
Q2 25
-11.6%
-50.8%
Q1 25
-382.7%
-29.9%
Q4 24
9.2%
-26.0%
Q3 24
-11.1%
-19.3%
Q2 24
14.3%
-17.8%
Q1 24
-1.9%
-27.6%
EPS (diluted)
ASPN
ASPN
HCAT
HCAT
Q4 25
$-0.87
$-1.29
Q3 25
$-0.08
$-0.32
Q2 25
$-0.11
$-0.59
Q1 25
$-3.67
$-0.35
Q4 24
$0.15
$-0.33
Q3 24
$-0.17
$-0.24
Q2 24
$0.21
$-0.23
Q1 24
$-0.02
$-0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASPN
ASPN
HCAT
HCAT
Cash + ST InvestmentsLiquidity on hand
$156.9M
$95.7M
Total DebtLower is stronger
$65.5M
$153.3M
Stockholders' EquityBook value
$235.5M
$245.8M
Total Assets
$406.7M
$502.6M
Debt / EquityLower = less leverage
0.28×
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASPN
ASPN
HCAT
HCAT
Q4 25
$156.9M
$95.7M
Q3 25
$150.7M
$91.5M
Q2 25
$167.6M
$97.3M
Q1 25
$192.0M
$342.0M
Q4 24
$220.9M
$392.0M
Q3 24
$113.5M
$387.3M
Q2 24
$91.4M
$308.3M
Q1 24
$101.5M
$327.8M
Total Debt
ASPN
ASPN
HCAT
HCAT
Q4 25
$65.5M
$153.3M
Q3 25
$70.1M
$153.1M
Q2 25
$77.3M
$153.0M
Q1 25
$95.4M
$382.9M
Q4 24
$95.0M
$382.4M
Q3 24
$93.7M
$345.0M
Q2 24
Q1 24
Stockholders' Equity
ASPN
ASPN
HCAT
HCAT
Q4 25
$235.5M
$245.8M
Q3 25
$305.7M
$331.9M
Q2 25
$308.8M
$347.5M
Q1 25
$314.8M
$376.8M
Q4 24
$614.7M
$365.2M
Q3 24
$507.6M
$355.0M
Q2 24
$517.8M
$357.0M
Q1 24
$491.2M
$357.2M
Total Assets
ASPN
ASPN
HCAT
HCAT
Q4 25
$406.7M
$502.6M
Q3 25
$491.4M
$587.1M
Q2 25
$525.1M
$616.2M
Q1 25
$555.0M
$891.5M
Q4 24
$895.1M
$858.9M
Q3 24
$782.6M
$813.0M
Q2 24
$748.6M
$691.7M
Q1 24
$698.0M
$695.1M
Debt / Equity
ASPN
ASPN
HCAT
HCAT
Q4 25
0.28×
0.62×
Q3 25
0.23×
0.46×
Q2 25
0.25×
0.44×
Q1 25
0.30×
1.02×
Q4 24
0.15×
1.05×
Q3 24
0.18×
0.97×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASPN
ASPN
HCAT
HCAT
Operating Cash FlowLast quarter
$16.1M
$9.9M
Free Cash FlowOCF − Capex
$13.7M
$9.6M
FCF MarginFCF / Revenue
33.1%
12.9%
Capex IntensityCapex / Revenue
6.0%
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-4.6M
$-697.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASPN
ASPN
HCAT
HCAT
Q4 25
$16.1M
$9.9M
Q3 25
$15.0M
$-464.0K
Q2 25
$-3.9M
$-9.0M
Q1 25
$5.6M
$280.0K
Q4 24
$35.7M
$-3.5M
Q3 24
$20.8M
$6.2M
Q2 24
$6.8M
$1.6M
Q1 24
$-17.7M
$10.3M
Free Cash Flow
ASPN
ASPN
HCAT
HCAT
Q4 25
$13.7M
$9.6M
Q3 25
$5.9M
$-719.0K
Q2 25
$-16.8M
$-9.2M
Q1 25
$-7.4M
$-390.0K
Q4 24
$20.9M
$-3.9M
Q3 24
$-50.0K
$5.5M
Q2 24
$-18.0M
$1.3M
Q1 24
$-43.6M
$10.1M
FCF Margin
ASPN
ASPN
HCAT
HCAT
Q4 25
33.1%
12.9%
Q3 25
8.1%
-0.9%
Q2 25
-21.6%
-11.4%
Q1 25
-9.4%
-0.5%
Q4 24
17.0%
-4.9%
Q3 24
-0.0%
7.2%
Q2 24
-15.3%
1.7%
Q1 24
-46.1%
13.5%
Capex Intensity
ASPN
ASPN
HCAT
HCAT
Q4 25
6.0%
0.4%
Q3 25
12.5%
0.3%
Q2 25
16.5%
0.3%
Q1 25
16.5%
0.8%
Q4 24
12.0%
0.5%
Q3 24
17.7%
0.9%
Q2 24
21.1%
0.4%
Q1 24
27.4%
0.3%
Cash Conversion
ASPN
ASPN
HCAT
HCAT
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
3.14×
Q3 24
Q2 24
0.41×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASPN
ASPN

Energy Industrial$14.5M35%
Other$13.9M34%
Thermal Barrier$12.9M31%

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

Related Comparisons